Clinical cardiology
-
Clinical cardiology · Jul 2011
Randomized Controlled TrialRanolazine for the treatment of heart failure with preserved ejection fraction: background, aims, and design of the RALI-DHF study.
Heart failure with preserved ejection fraction (HFpEF), formerly referred to as diastolic heart failure (DHF), accounts for >50% of all HF patients. So far, there has been no specific treatment for impaired left ventricular (LV) relaxation. Data from in vitro and animal studies indicate that ranolazine improves diastolic function by inhibiting the late sodium current. ⋯ The RALI-DHF study is designed as a translational study to bridge the gap between basic science and therapeutics and to determine if ranolazine, compared with placebo, will be more effective in improving diastolic function in patients with HFpEF.